{"cluster": 61, "subcluster": 0, "abstract_summ": "BACKGROUND: Vaccines are the most reliable alternative to elicit sterile immunity against malaria but their development has been hindered by polymorphisms and strain-specificity in previously studied antigens.BACKGROUND: During the erythrocytic cycle, Plasmodium falciparum malaria parasites express P. falciparum Erythrocyte Membrane Protein 1 (PfEMP1) that anchor the infected erythrocytes (IE) to the vascular lining of the host.CONCLUSIONS: This work provides proof-of-concept for the validity of this mass spectrometry/bioinformatic approach for future studies seeking to reveal malaria liver stage antigens towards vaccine development.BACKGROUND: There is an urgent need for an effective vaccine to control and eradicate malaria, one of the most serious global infectious diseases.CONCLUSIONS: The study observations mirror those from previous CIDR\u03b11 vaccine studies using other vaccine constructs and platforms.", "title_summ": "Genetic polymorphisms in malaria vaccine candidate Plasmodium falciparum reticulocyte-binding protein homologue-5 among populations in Lagos, NigeriaIdentification of Plasmodium falciparum proteoforms from liver stage modelsStrains used in whole organism Plasmodium falciparum vaccine trials differ in genome structure, sequence, and immunogenic potentialIdentification, molecular characterization and expression of aminopeptidase N-1 (APN-1) from Anopheles stephensi in SF9 cell line as a candidate molecule for developing a vaccine that interrupt malaria transmissionPattern of antibody responses to Plasmodium falciparum antigens in individuals differentially exposed to Anopheles bitesMicroarray analyses reveal strain-specific antibody responses to Plasmodium falciparum apical membrane antigen 1 variants following natural infection and vaccinationImmunization with virus-like particles conjugated to CIDR\u03b11 domain of Plasmodium falciparum erythrocyte membrane protein 1 induces inhibitory antibodiesImmunogenicity analysis of conserved fragments in Plasmodium ovale species merozoite surface protein 4Plasmodium vivax HAP2/GCS1 gene exhibits limited genetic diversity among parasite isolates from the Greater Mekong SubregionThe malaria parasite Plasmodium falciparum in red blood cells selectively takes up serum proteins that affect host pathogenicityAntibodies against a short region of PfRipr inhibit Plasmodium falciparum merozoite invasion and PfRipr interaction with Rh5 and SEMA7AGenetic polymorphism of merozoite surface protein-3 in Myanmar Plasmodium falciparum field isolatesImmunolocalization of Disorganized Muscle Protein-1 in Different Life Stages of Human Lymphatic Filariid, Brugia malayi", "title_abstract_phrases": "[Image: see text]The malaria parasite Plasmodium falciparum in red blood cells selectively takes up serum proteins that affect host pathogenicityBACKGROUND: The malaria parasite Plasmodium falciparum is a protozoan that develops in red blood cells (RBCs) and requires various host factors.Genetic polymorphisms in malaria vaccine candidate Plasmodium falciparum reticulocyte-binding protein homologue-5 among populations in Lagos, NigeriaBACKGROUND: Vaccines are the most reliable alternative to elicit sterile immunity against malaria but their development has been hindered by polymorphisms and strain-specificity in previously studied antigens.Immunogenicity analysis of conserved fragments in Plasmodium ovale species merozoite surface protein 4BACKGROUND: There is an urgent need for an effective vaccine to control and eradicate malaria, one of the most serious global infectious diseases.Immunization with virus-like particles conjugated to CIDR\u03b11 domain of Plasmodium falciparum erythrocyte membrane protein 1 induces inhibitory antibodiesBACKGROUND: During the erythrocytic cycle, Plasmodium falciparum malaria parasites express P. falciparum Erythrocyte Membrane Protein 1 (PfEMP1) that anchor the infected erythrocytes (IE) to the vascular lining of the host.Strains used in whole organism Plasmodium falciparum vaccine trials differ in genome structure, sequence, and immunogenic potentialBACKGROUND: Plasmodium falciparum (Pf) whole-organism sporozoite vaccines have been shown to provide significant protection against controlled human malaria infection (CHMI) in clinical trials."}